Trump administration readies new tariffs on select drugmakers, Bloomberg News reports

• Pfizer and AstraZeneca have secured multi-year tariff exemptions through pricing deals and commitments to the TrumpRx.gov platform
• Eli Lilly, Johnson & Johnson, and Merck have pledged billions to expand U.S. manufacturing operations to avoid the 100% tariff penalty
• The tariff threat has prompted global drugmakers to ramp up U.S. manufacturing and stockpile inventory in anticipation of potential trade penalties

Summary

The Trump administration plans to announce new tariffs on pharmaceutical companies as soon as Thursday, targeting drugmakers that haven't agreed to pricing deals guaranteeing lower U.S. drug costs, according to Bloomberg News sources.

Key Details:

• Tariff rate: 100% on imported branded and patented medicines for non-compliant companies
• Exemption criteria: Companies must secure pricing agreements and commit to the TrumpRx.gov platform
• Timeline: Announcement expected April 1st (Thursday)

Companies with Secured Exemptions:

• Pfizer and AstraZeneca have obtained multi-year tariff exemptions through pricing deals and platform commitments

Companies Avoiding Penalties:

• Eli Lilly, Johnson & Johnson, and Merck have pledged billions of dollars to expand U.S. manufacturing operations

Market Implications:

The tariff threat has already prompted global pharmaceutical manufacturers to:

• Ramp up U.S.-based manufacturing capacity
• Stockpile inventory domestically
• Negotiate pricing agreements with the administration

Companies without agreements or active negotiations face the full 100% tariff penalty. However, the report notes plans remain fluid and could change before final announcement. Potential exemptions may apply to specific medicines or disease categories.

Industry Impact:

This policy represents a significant shift in pharmaceutical trade policy, using tariffs as leverage to reduce U.S. drug prices while incentivizing domestic manufacturing. The move creates a two-tier system favoring companies willing to commit to lower pricing and domestic production investments.

The White House has not yet responded to requests for comment on the reported plans.